Veliparib (dihydrochloride)

[1]Donawho CK, et al. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13 (9) :2728-37.|[2]Penning TD, et al. Discovery of the Poly (ADP-ribose) polymerase (PARP) inhibitor 2-[ (R) -2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2009 Jan 22;52 (2) :514-23.|[3]Albert JM, et al. Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007 May 15;13 (10) :3033-42.|[4]Robert J. Kinders, et al. Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts. Clin Cancer Res. Author manuscript; available in PMC 2009 Nov 1.

Electrostatics Joint Conference. 2016 July.|Harvard Medical School LINCS LIBRARY|Int J Curr Res Acad Rev. 2017; 5 (3) : 53-64.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Patent. US20200078369A1|Patent. US20200129476A1|Acta Pharmacol Sin. 2022 Apr;43 (4) :781-787.|Adv Sci (Weinh) . 2025 Jul 16:e15585.|Adv Sci (Weinh) . 2025 Jun 25:e02448.|Analyst. 2025 Dec 1;150 (24) :5501-5513.|Biomed Res Int. 2023 Feb 6:2023:7891753.|bioRxiv. 2025 Nov 4:2025.11.03.686423.|BMC Cancer. 2022 Mar 23;22 (1) :312.|Cancer Discov. 2017 Sep;7 (9) :984-998.|Cancer Genet. 2019 Nov:239:26-32.|Cancer Res. 2025 May 14.|Cancers (Basel) . 2024 Nov 5;16 (22) :3728.|Cancers (Basel) . 2024 Oct 10;16 (20) :3441.|Cell Death Dis. 2024 Dec 18;15 (12) :914.|Cell Signal. 2025 Jul:131:111709.|Cells. 2021 Mar 9;10 (3) :599.|Clin Cancer Res. 2017 Feb 15;23 (4) :1001-1011. |Ecotoxicol Environ Saf. 2023 Mar 1:252:114630.|EJNMMI Res. 2025 Apr 29;15 (1) :50.|Front Mol Biosci. 2021 Apr 29:8:633344.|Front Oncol. 2021 Jul 9:11:681441.|Int J Biol Macromol. 2023 Jul 1;242 (Pt 2) :124794.|J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 1;1154:122195.|J Invest Dermatol. 2024 May 30:S0022-202X (24) 00384-1.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Transl Med. 2024 Nov 26;22 (1) :1062.|J Vet Med Sci. 2018 Nov 23;80 (11) :1775-1781. |Mol Cancer Ther. 2019 Nov;18 (11) :2063-2073.|Nanomaterials. 2021 Jun 8;11 (6) :1514.|Nat Chem Biol. 2025 Jun 27.|Nat Commun. 2021 Jun 24;12 (1) :3931.|Nature. 2025 Sep;645 (8082) :1071-1080.|Neoplasia. 2018 Mar 28;20 (5) :478-488. |Neoplasia. 2025 May:63:101152.|Neoplasia. 2019 Apr 24;21 (6) :533-544. |Oncogene. 2022 Sep;41 (37) :4271-4281.|Oncol Lett. 2025 Jan 7;29 (3) :128.|Patent. US20180263995A1.|Patent. US20180362972A1.|Res Sq. 2024 Feb 21:rs.3.rs-3970470.|Research Square Preprint. 2021 Feb.|Research Square Preprint. 2024 Nov 06.|Sci Signal. 2025 Oct 21;18 (909) :eadx2532.|Theranostics. 2020 Jul 25;10 (21) :9477-9494.